
Talha Badar: In view of recent approval of IDH1i in MDS brief tweetorial
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:
”Weekend review!
In view of recent approval of IDH1i in MDS.
IDH1m present in 3% of pts with MDS.
Earlier approved for RR AML with IDH1m and AML ineligible for IC.
Brief tweetorial.
Retrospective analysis suggests, MDS points with neutropenia, regardless of IPSS-R, more enriched with IDH1/2 and these can potentially targeted with IDHi.
First in human, single arm phase dose escalation study, 16 pts Rx @ 500 mg OD. CR 44%, 60% maintained response at 1 year (NCT02074839).
The idiome phase 2 study by the GFM group; evaluated IDHi in MDS failing HMA or HR-MDS. 32 pts treated, ORR was 69%, CR 46%. DOR 7.4 mo, OS 14 mo (91% response rate in treatment naive HR-MDS).
20 pts with MDS Rx with Olutasidenib (highly selective and potent) IDH1i, 6 alone and 14 with AZA. Clinical responses were seen in 33% with alone and 73% with combo.
Recently published study on Olutasidenib in MDS/AML 78 pts (46 with combo) Rx, response rate in the range of 40%, comparable b/w mono and combo therapy.
After FDA breakthrough designation, enrollment was expanded: 19 pts were Rx (78.9% with HMA failure) mOS 35.7 mo. 15/18 had ORR,CR 39% mDOR not reached at data cut off. Median time to response 1.9 mo Approval is based on study of 18 pts ONLY!
Conclusion Albeit study with small sample size and IDH1m occurrence in only 3-4% of MDS Seems to be effective target, highly encouraging responses post HMA failure! ORR up-to 90% in treatment naive MDS.”
Source: Talha Badar/Twitter
-
12:46 30/11/23 | BlogJohanna Joyce: the Flashlight method
-
12:31 30/11/23 | InsightJeff Ryckman: Omitting RT in bulky early-stage cHL
-
07:45 30/11/23 | BlogAaron Goodman: Hemoglobin Dissociation Curve! Good stuff
-
12:31 30/11Jeff Ryckman: Omitting RT in bulky early-stage cHL
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows